ClinicalTrials.gg
CompletedNCT02013622Updated Mar 29, 2016Results posted

Monotherapy Brexpiprazole (OPC-34712) Trial in the Treatment of Adults With Early-Episode Schizophrenia

A Phase 3 interventional study of Brexpiprazole in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 22 sites in United States. Open to participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2016-03-29.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
49
Allocation
Not applicable
Ages
18 Years to 35 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing brexpiprazole in Schizophrenia — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Schizophrenia.

Enrollment
18th of 28
49 · median 155
Started
2013
with 5 others
Phase 3
16 of 28
none open now
Registered
16th of 28
by date
Lead sponsor
19 of 28
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 28 studies testing brexpiprazole in Schizophrenia, this one is the 18th largest by enrollment, is one of 6 that started in 2013, is one of 16 in phase 3, and was the 16th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 28 studies testing brexpiprazole in Schizophrenia is open now. Recruiting first, the newest first:

About brexpiprazole

brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 35 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing brexpiprazole in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the effects of flexibly dosed Brexpiprazole monotherapy in the improvement of early-episode schizophrenia through the assessment of social functioning, efficacy, and tolerability. Early-episode schizophrenia is defined as episodes occurring ≤ 5 years after the onset of the first episode.

03

Conditions studied

  • Schizophrenia

Keywords

  • schizophrenia
  • Mental Disorders
  • Psychotic Disorders
  • social avoidance
  • emotional withdrawal
  • passive/apathetic
  • social withdrawal
  • antipsychotic
04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Have a diagnosis of schizophrenia as defined by the , Fourth Edition, Text Revision (DSM-IV-TR) and confirmed by both the Mini International Neuropsychiatric Interview (M.I.N.I.) for Schizophrenia and Psychotic Disorders Studies and an adequate clinical psychiatric evaluation.

  • Had the start of their first schizophrenia episode ≤ 5 years before the time of consent.
  • Are 18 to 35 years old at the time of consent (inclusive, and outpatients only).
  • Have a Positive and Negative Syndrome Scale (PANSS) Total Score of ≤ 80 at screening and baseline.
  • Exhibit schizophrenia symptoms with a score ≥ 4 on the PANSS for ≥1 items related to active social avoidance, emotional withdrawal, passive/apathetic social withdrawal, and difficulty in abstract thinking.
  • Have a diagnosis of schizophrenia made at least 6 months prior to screening as confirmed by subject, caregiver, or documented history.

Exclusion Criteria: Subjects presenting with a first episode of schizophrenia based on the clinical judgment of the investigator.

  • Subjects who have been hospitalized for psychotic symptoms within the last 6 months.
  • Subjects with schizophrenia who are considered resistant/ to antipsychotic treatment by history or who have a history of failure to respond to clozapine or response to clozapine treatment only.
  • Subjects with a current DSM-IV-TR Axis I diagnosis other than schizophrenia, including, but not limited to, schizoaffective disorder, MDD, bipolar disorder, post-traumatic stress disorder, anxiety disorders, delirium, dementia, amnestic, or other cognitive disorders. Also, subjects with borderline, paranoid, histrionic, schizotypal, schizoid, or antisocial personality disorders.
  • Subjects experiencing acute depressive symptoms within the past 30 days, according to the investigator's opinion, that require treatment with an antidepressant.
  • Subjects with tardive dyskinesia at enrollment, as determined by a score of>= 3 on Item 8 of the AIMS at screening or baseline.
  • Subjects with a score of 5 (severe akathisia) on the BARS global clinical assessment of akathisia at screening or baseline.
  • Subjects who have met DSM-IV-TR criteria for substance abuse or dependence within the past 180 days; including alcohol and benzodiazepines, but excluding nicotine.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
49 participants (actual)

Study arms

  • Experimental
    Brexpiprazole

    Up to 4 mg/day, once daily dose, tablets, orally

    Drug: Brexpiprazole

Interventions

  • Treatment (16 weeks) Up to 4 mg/day, once daily dose, tablets, orally

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline to Week 16 in Positive and Negative Syndrome Scale (PANSS) Total Score

    The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

    Time frame: Baseline and Week 16

Secondary outcomes

  1. Mean Change From Baseline to Week 16 Scores of the Following Negative Scale Items: Active Social Avoidance, Emotional Withdrawal, Passive/Apathetic Social Withdrawal, and Difficulty in Abstract Thinking

    The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS Negative Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).

    Time frame: Baseline and Week 16

  2. Mean Change From Baseline to Week 16 in Clinical Global Impression-Severity (CGI-S) Score

    The severity of illness for each participant was rated using the CGI-S. To perform this assessment, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

    Time frame: Baseline and Week 16

  3. Mean Clinical Global Impression-Improvement (CGI-I) Score

    The improvement of each participants condition was rated for each participant using the CGI-I. The study physician rated the participants total improvement whether or not it was due entirely to drug treatment. To perform this assessment, the study physician answered the following question: "Compared to his/her condition at baseline, how much has the participant changed?" Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The response at a given week was compared with the participants condition at Baseline prior to the first dose of study medication.

    Time frame: Week 1 to Week 16

  4. CGI-I Response Rate

    The CGI-I response rate was defined as percentage of participants with CGI-I score of 1 (very much improved) or 2 (much improved).

    Time frame: Weeks 4, 8, 12, and 16

  5. Mean Change From Baseline to Week 16 in Personal and Social Performance (PSP) Total Score

    The PSP was used to measure personal and social functioning in 4 domains: socially useful activities (e.g., work and study), personal and social relationships, self-care, and disturbing and aggressive behaviors. Impairment in each of these domains was rated as absent, mild, manifest, marked, severe, or very severe. These ratings were then converted to a total score based on a 100-point scale using algorithms to identify the appropriate 10-point interval, and the study physician's judgment to determine the total score within the 10-point interval. Participants with a PSP total score of 71 to 100 were considered to have mild functional difficulty. Scores of 31 to 70 represented manifest disabilities of various degrees, and ratings of 1 to 30 indicated minimal functioning that required intense support and/or supervision.

    Time frame: Baseline and Week 16

  6. Mean Change From Baseline to Week 16 in Specific Levels of Functioning (SLOF) Total Score

    The SLOF questionnaire used in this trial consists of 30 items grouped into 4 areas: social functioning, social acceptability, activities, and work skill. The SLOF scale correlates with a participant's quality of life. Total SLOF scale is sum of these 4 areas score. Each of the questions in the above domains is rated on a 5-point Likert scale. Scores on the instrument range from 30 to 150 with higher scores indicating the better the overall functioning of the patient.

    Time frame: Baseline and Week 16

  7. Mean Change From Baseline to Week 16 in Pittsburgh Sleep Quality Index (PSQI) Total Score

    The PSQI was a self-rated questionnaire that assessed sleep quality and disturbances over a 1-month time interval. Seven domains were measured: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction over the last month. The PSQI contains 19 self-rated questions and 5 questions rated by the bed partner or roommate (if 1 is available). Only self-rated questions are included in the scoring.The 19 self-rated items are combined to form 7 "component" scores, each of which has a range of 0 - 3 points. In all cases, a score of "0" indicates no difficulty, while a score of "3" indicates severe difficulty. The 7 component scores are then added to yield 1 "global" score, with a range of 0 - 21 points, "0" indicating no difficulty and "21" indicating severe difficulties in all areas.

    Time frame: Baseline and Week 16

  8. Mean Change From Baseline to Week 16 in Treatment Satisfaction Questionnaire for Medication (TSQM) Total Score

    The TSQM-14 was a participant-rated scale used to assess subjective satisfaction with medication. The TSQM-14 provided scores on 4 domains: effectiveness (questions 1 to 3) side effects (4 to 8), convenience (9 to 11), and global satisfaction (12 to 14). The effectiveness domain was rated on a 7-point scale from "extremely satisfied" to "extremely dissatisfied." The side effects domain provided an option to skip questions 5 to 8 if the subject provided a negative response to item number 4, ie, "As a result of taking this medication, do you currently experience any side effects at all?" Scores for each domain were transformed into a final score ranging from 0 to 100, with higher numbers indicating a higher level of satisfaction.

    Time frame: Baseline and Week 16

  9. Mean Change From Baseline to Week 16 in Go/No-Go Task (P-inhibition Failures)

    Executive function and working memory were assessed using computer based neuropsychological instruments at Baseline and Week 16/Early Termination (ET). These instruments focused on measuring impulse inhibition. Proportions of inhibitory failures (p-inhibitory failures) is measured as the proportion of no-go targets in the go-cue condition in which a participant failed to inhibit a response.

    Time frame: Baseline and Week 16

  10. Mean Change From Baseline to Week 16 in Go/No-Go Task (Mean Reaction Time)

    Executive function and working memory were assessed using computer based neuropsychological instruments at Baseline and Week 16/Early Termination (ET). These instruments focused on measuring impulse inhibition.

    Time frame: Baseline and Week 16

  11. Mean Change From Baseline to Week 16 in Delay Discounting Task - Monetary Choice Questionnaire (MCQ) Scores

    Delay discounting was a participant-completed task is an index of impulsive behavior. It measured the extent to which the value of a reward decreased as the delay to obtaining that reward increased. The propensity of participants to delay reward was assessed with an MCQ. Discounting rate is estimated using, k= (A/V)1/D, where k is the discounting rate parameter, V is the immediate reward, A is the higher delayed reward and D is the amount of days to the delayed reward. The MCQ consists of 27 choices between immediate and delayed rewards. The participant chooses repeatedly between 2 hypothetical sums of money: a smaller amount now or a larger amount in the future (for example, "would you prefer $27 today or $50 in 21 days?") The answers provide an estimate of the participant's discounting rate; higher discounting rates indicate greater impulsivity. A total score is not computed for all 27 questions.

    Time frame: Baseline and Week 16

  12. Mean Change From Baseline to Week 16 in Delay and Probability Discounting Task (DPDT) - Experiential Discounting Task Scores

    Delay discounting measures the extent to which the value of a reward decreased as the delay to obtaining that reward increased. The propensity of participants to delay reward was assessed with an MCQ with completion of an Experiential Discounting task (EDT). The participant chose between different amounts of money available at different delays or with different chances (probability to get the money). At the end of the session, one of the choices was selected at random, and the participant received whatever they chose in response of that question (immediate, delayed, or probabilistic amount). Formula for h-value:value = A / (1 + hO) p is probability of reward and O is odds against.The value of h indicates how the value of a reward and the probability of its occurrence decreases. The data are computerized and reflect delay discounting and impulsivity (higher discounting and higher Probability discounting shows greater impulsivity). A total score is not computed for this task.

    Time frame: Baseline and Week 16

  13. Change From Baseline to Week 16 in the Mean Number of Impulsive Choices in the Delayed Reward Task (DRT)

    Delay discounting was a participant-completed task considered as an index of impulsive behavior. It measured the extent to which the value of a reward decreased as the delay to obtaining that reward increased. During a training session, a single button with letter A or B appeared on the screen. The participant had to wait until the letter began to flash, and press the button only once. An amount of money was added to a counter and another single button appeared. During the test session, both buttons with letters A and B appeared on the screen. The participant had to choose one of the letters that remained; the other disappeared. The participant had to wait until the letter began to flash and then press the button again. An amount of money was added to the counter, and both letters appeared again. The data are computerized and reflect delay discounting and impulsivity (higher discounting shows greater impulsivity). A total score was not calculated for this task.

    Time frame: Baseline and Week 16

  14. Mean Change From Baseline to Week 16 in Food Delay Discounting Task

    Delay discounting was a participant-completed task considered as an index of impulsive behavior. The participant chooses between a reward they could have today and another that they could get after a specified amount of time. The participant would not receive the rewards, but was asked to make decisions as though he or she were really going to receive them. AUC is defined as area under the concentration-time curve; AUC for food is presented below. The data are computerized and reflect delay discounting and impulsivity (higher discounting shows greater impulsivity). To calculate the AUC, the "X-axis" is "days", "Y-axis" is "Food value", the actual area underneath the curve was calculated by summing the results for each delay and present value pair: x2 -x1\[(y1 + y2)/2\], where x1 and x2 are successive delays and y1 and y2 are the present values associated with those delays. The AUC can range from 1 (no discounting) to 0 (maximum discounting).

    Time frame: Baseline and Week 16

  15. Mean Change From Baseline to Week 16 in Money Delay Discounting Task

    Delay discounting was a participant-completed task considered as an index of impulsive behavior. The participant chose between a reward they could have today and another that they could get after a specified amount of time. The participant would not receive the rewards, but was asked to make decisions as though he or she were really going to receive them. AUC is defined as area under the concentration-time curve; AUC for money is presented below. The data are computerized and reflect delay discounting and impulsivity (higher discounting shows greater impulsivity). To calculate the AUC, the "X-axis" is "days", "Y-axis" is "Money value", the actual area underneath the curve was calculated by summing the results for each delay and present value pair: x2 -x1\[(y1 + y2)/2\], where x1 and x2 are successive delays and y1 and y2 are the present values associated with those delays. The AUC can range from 1 (no discounting) to 0 (maximum discounting).

    Time frame: Baseline and Week 16

  16. Mean Change From Baseline to Week 16 in Barratt Impulsiveness Scale (BIS) 11-Item

    The BIS-11 was a participant-rated scale designed to assess impulsive personality traits. The BIS-11 consisted of 30 items scored on a 4-point scale ranging from 1 (rarely/never) to 4 (almost always/always). The scores provided information to assess 6 first-order factors (attention, motor, self-control, cognitive complexity, perseverance, and cognitive instability impulsiveness) and 3 second-order factors (motor impulsiveness, non-planning impulsiveness, and attentional impulsiveness). The total score ranged from 30 to 120, with higher scores indicating impulsive personality traits. It took 10 to 15 minutes to complete the BIS-11. The BIS-11 was administered at the following visits: Baseline and Week 16/ET.

    Time frame: Baseline and Week 16

07

Results

Posted Mar 29, 2016

Participant flow

This was an exploratory phase 3b, multicenter, open-label, monotherapy, flexible-dose brexpiprazole trial designed to assess the efficacy and safety of brexpiprazole in participants with early-episode schizophrenia.

Participant flow — Overall Study
MilestoneBrexpiprazole
Started49
Completed25
Not completed24
Withdrew: Lost to follow-up10
Withdrew: Adverse event3
Withdrew: Met withdrawal criteria3
Withdrew: Withdrawal by subject6
Withdrew: Protocol deviation1
Withdrew: Lack of efficacy1

Outcome measures

PrimaryMean Change From Baseline to Week 16 in Positive and Negative Syndrome Scale (PANSS) Total Score

The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS total score was the sum of the rating scores for 7 positive scale items, 7 negative scale items, and 16 general psychopathology scale items from the PANSS panel. The PANSS total score ranged from 30 (best possible outcome) to 210 (worst possible outcome).

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline to Week 16 in Positive and Negative Syndrome Scale (PANSS) Total Score
Units on a scaleBrexpiprazole
Mean Change From Baseline to Week 16 in Positive and Negative Syndrome Scale (PANSS) Total Score-10.2 ± 2.1
Statistical analysis
  • Brexpiprazole · Mixed Models Analysis · p = <0.0001Mixed model repeated measures (MMRM) method with model terms: baseline, visit, and baseline by visit interaction.
SecondaryMean Change From Baseline to Week 16 Scores of the Following Negative Scale Items: Active Social Avoidance, Emotional Withdrawal, Passive/Apathetic Social Withdrawal, and Difficulty in Abstract Thinking

The PANSS consisted of three subscales: a total of 30 symptom constructs. For each symptom construct, severity was rated on a 7-point scale, with a score of 1 (absence of symptoms) and a score of 7 (extremely severe symptoms). The PANSS negative subscale score was the sum of the rating scores for the 7 negative scale items from the PANSS panel. The 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive apathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking. The PANSS Negative Subscale ranges from 7 (absence of symptoms) to 49 (extremely severe symptoms).

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline to Week 16 Scores of the Following Negative Scale Items: Active Social Avoidance, Emotional Withdrawal, Passive/Apathetic Social Withdrawal, and Difficulty in Abstract Thinking
Units on a scaleBrexpiprazole
Mean Change From Baseline to Week 16 Scores of the Following Negative Scale Items: Active Social Avoidance, Emotional Withdrawal, Passive/Apathetic Social Withdrawal, and Difficulty in Abstract Thinking-2.0 ± 0.4
Statistical analysis
  • Brexpiprazole · Mixed Models Analysis · p = <0.0001MMRM method with model terms: baseline, visit, and baseline by visit interaction.
SecondaryMean Change From Baseline to Week 16 in Clinical Global Impression-Severity (CGI-S) Score

The severity of illness for each participant was rated using the CGI-S. To perform this assessment, the study physician answered the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices included: 0 = not assessed; 1 = normal, not at all ill; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline to Week 16 in Clinical Global Impression-Severity (CGI-S) Score
Units on a scaleBrexpiprazole
Mean Change From Baseline to Week 16 in Clinical Global Impression-Severity (CGI-S) Score-0.6 ± 0.1
Statistical analysis
  • Brexpiprazole · Mixed Models Analysis · p = <0.0001MMRM method with model terms: baseline, visit, and baseline by visit interaction.
SecondaryMean Clinical Global Impression-Improvement (CGI-I) Score

The improvement of each participants condition was rated for each participant using the CGI-I. The study physician rated the participants total improvement whether or not it was due entirely to drug treatment. To perform this assessment, the study physician answered the following question: "Compared to his/her condition at baseline, how much has the participant changed?" Response choices included: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The response at a given week was compared with the participants condition at Baseline prior to the first dose of study medication.

Time frame:
Week 1 to Week 16
Reported as:
Mean · Units on a scale
Mean Clinical Global Impression-Improvement (CGI-I) Score
Units on a scaleBrexpiprazole
Week 13.6 ± 0.7
Week 23.1 ± 1.0
Week 32.7 ± 1.1
Week 42.8 ± 1.1
Week 62.7 ± 1.2
Week 82.9 ± 1.2
Week 102.8 ± 1.3
Week 122.8 ± 1.3
Week 142.9 ± 1.3
Week 162.8 ± 1.3
SecondaryCGI-I Response Rate

The CGI-I response rate was defined as percentage of participants with CGI-I score of 1 (very much improved) or 2 (much improved).

Time frame:
Weeks 4, 8, 12, and 16
Reported as:
Number · percentage of participants
CGI-I Response Rate
percentage of participantsBrexpiprazole
Week 439.6
Week 835.4
Week 1241.7
Week 1641.7
SecondaryMean Change From Baseline to Week 16 in Personal and Social Performance (PSP) Total Score

The PSP was used to measure personal and social functioning in 4 domains: socially useful activities (e.g., work and study), personal and social relationships, self-care, and disturbing and aggressive behaviors. Impairment in each of these domains was rated as absent, mild, manifest, marked, severe, or very severe. These ratings were then converted to a total score based on a 100-point scale using algorithms to identify the appropriate 10-point interval, and the study physician's judgment to determine the total score within the 10-point interval. Participants with a PSP total score of 71 to 100 were considered to have mild functional difficulty. Scores of 31 to 70 represented manifest disabilities of various degrees, and ratings of 1 to 30 indicated minimal functioning that required intense support and/or supervision.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline to Week 16 in Personal and Social Performance (PSP) Total Score
Units on a scaleBrexpiprazole
Mean Change From Baseline to Week 16 in Personal and Social Performance (PSP) Total Score6.6 ± 1.7
Statistical analysis
  • Brexpiprazole · Mixed Models Analysis · p = 0.0003MMRM method with model terms: baseline, visit, and baseline by visit interaction.
SecondaryMean Change From Baseline to Week 16 in Specific Levels of Functioning (SLOF) Total Score

The SLOF questionnaire used in this trial consists of 30 items grouped into 4 areas: social functioning, social acceptability, activities, and work skill. The SLOF scale correlates with a participant's quality of life. Total SLOF scale is sum of these 4 areas score. Each of the questions in the above domains is rated on a 5-point Likert scale. Scores on the instrument range from 30 to 150 with higher scores indicating the better the overall functioning of the patient.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline to Week 16 in Specific Levels of Functioning (SLOF) Total Score
Units on a scaleBrexpiprazole
Mean Change From Baseline to Week 16 in Specific Levels of Functioning (SLOF) Total Score13.1 ± 3.1
Statistical analysis
  • Brexpiprazole · Mixed Models Analysis · p = 0.0002MMRM method with model terms: baseline, visit, and baseline by visit interaction.
SecondaryMean Change From Baseline to Week 16 in Pittsburgh Sleep Quality Index (PSQI) Total Score

The PSQI was a self-rated questionnaire that assessed sleep quality and disturbances over a 1-month time interval. Seven domains were measured: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction over the last month. The PSQI contains 19 self-rated questions and 5 questions rated by the bed partner or roommate (if 1 is available). Only self-rated questions are included in the scoring.The 19 self-rated items are combined to form 7 "component" scores, each of which has a range of 0 - 3 points. In all cases, a score of "0" indicates no difficulty, while a score of "3" indicates severe difficulty. The 7 component scores are then added to yield 1 "global" score, with a range of 0 - 21 points, "0" indicating no difficulty and "21" indicating severe difficulties in all areas.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline to Week 16 in Pittsburgh Sleep Quality Index (PSQI) Total Score
Units on a scaleBrexpiprazole
Mean Change From Baseline to Week 16 in Pittsburgh Sleep Quality Index (PSQI) Total Score-1.8 ± 0.7
Statistical analysis
  • Brexpiprazole · Mixed Models Analysis · p = 0.0177MMRM method with model terms: baseline, visit, and baseline by visit interaction.
SecondaryMean Change From Baseline to Week 16 in Treatment Satisfaction Questionnaire for Medication (TSQM) Total Score

The TSQM-14 was a participant-rated scale used to assess subjective satisfaction with medication. The TSQM-14 provided scores on 4 domains: effectiveness (questions 1 to 3) side effects (4 to 8), convenience (9 to 11), and global satisfaction (12 to 14). The effectiveness domain was rated on a 7-point scale from "extremely satisfied" to "extremely dissatisfied." The side effects domain provided an option to skip questions 5 to 8 if the subject provided a negative response to item number 4, ie, "As a result of taking this medication, do you currently experience any side effects at all?" Scores for each domain were transformed into a final score ranging from 0 to 100, with higher numbers indicating a higher level of satisfaction.

Time frame:
Baseline and Week 16
Reported as:
Least squares mean · Units on a scale
Mean Change From Baseline to Week 16 in Treatment Satisfaction Questionnaire for Medication (TSQM) Total Score
Units on a scaleBrexpiprazole
Effectiveness20.00 ± 4.09
Side effects10.25 ± 2.98
Convenience11.83 ± 2.92
Global satisfaction20.67 ± 4.33
Statistical analysis
  • Brexpiprazole · Mixed Models Analysis · p = <0.0001MMRM method with model terms: baseline, visit, and baseline by visit interaction.
  • Brexpiprazole · Mixed Models Analysis · p = 0.0031MMRM method with model terms: baseline, visit, and baseline by visit interaction.
  • Brexpiprazole · Mixed Models Analysis · p = 0.0005MMRM method with model terms: baseline, visit, and baseline by visit interaction.
  • Brexpiprazole · Mixed Models Analysis · p = <0.0001MMRM method with model terms: baseline, visit, and baseline by visit interaction.
SecondaryMean Change From Baseline to Week 16 in Go/No-Go Task (P-inhibition Failures)

Executive function and working memory were assessed using computer based neuropsychological instruments at Baseline and Week 16/Early Termination (ET). These instruments focused on measuring impulse inhibition. Proportions of inhibitory failures (p-inhibitory failures) is measured as the proportion of no-go targets in the go-cue condition in which a participant failed to inhibit a response.

Time frame:
Baseline and Week 16
Reported as:
Mean · failures
Mean Change From Baseline to Week 16 in Go/No-Go Task (P-inhibition Failures)
failuresBrexpiprazole
p-inhibition failures (go cues)0.045 ± 0.326
p-inhibition failures (no-go cues)0.066 ± 0.352
Statistical analysis
  • Brexpiprazole · t-test, 2 sided · p = 0.5133
  • Brexpiprazole · t-test, 2 sided · p = 0.3774
SecondaryMean Change From Baseline to Week 16 in Go/No-Go Task (Mean Reaction Time)

Executive function and working memory were assessed using computer based neuropsychological instruments at Baseline and Week 16/Early Termination (ET). These instruments focused on measuring impulse inhibition.

Time frame:
Baseline and Week 16
Reported as:
Mean · milliseconds
Mean Change From Baseline to Week 16 in Go/No-Go Task (Mean Reaction Time)
millisecondsBrexpiprazole
Mean reaction time (go cues)-2.05 ± 68.51
Mean reaction time (no-go cues)-18.77 ± 90.18
Statistical analysis
  • Brexpiprazole · t-test, 2 sided · p = 0.8897
  • Brexpiprazole · t-test, 2 sided · p = 0.3401
SecondaryMean Change From Baseline to Week 16 in Delay Discounting Task - Monetary Choice Questionnaire (MCQ) Scores

Delay discounting was a participant-completed task is an index of impulsive behavior. It measured the extent to which the value of a reward decreased as the delay to obtaining that reward increased. The propensity of participants to delay reward was assessed with an MCQ. Discounting rate is estimated using, k= (A/V)1/D, where k is the discounting rate parameter, V is the immediate reward, A is the higher delayed reward and D is the amount of days to the delayed reward. The MCQ consists of 27 choices between immediate and delayed rewards. The participant chooses repeatedly between 2 hypothetical sums of money: a smaller amount now or a larger amount in the future (for example, "would you prefer $27 today or $50 in 21 days?") The answers provide an estimate of the participant's discounting rate; higher discounting rates indicate greater impulsivity. A total score is not computed for all 27 questions.

Time frame:
Baseline and Week 16
Reported as:
Mean · unitless
Mean Change From Baseline to Week 16 in Delay Discounting Task - Monetary Choice Questionnaire (MCQ) Scores
unitlessBrexpiprazole
Mean Change From Baseline to Week 16 in Delay Discounting Task - Monetary Choice Questionnaire (MCQ) Scores0.008520 ± 0.056857
Statistical analysis
  • Brexpiprazole · t-test, 2 sided · p = 0.4265
SecondaryMean Change From Baseline to Week 16 in Delay and Probability Discounting Task (DPDT) - Experiential Discounting Task Scores

Delay discounting measures the extent to which the value of a reward decreased as the delay to obtaining that reward increased. The propensity of participants to delay reward was assessed with an MCQ with completion of an Experiential Discounting task (EDT). The participant chose between different amounts of money available at different delays or with different chances (probability to get the money). At the end of the session, one of the choices was selected at random, and the participant received whatever they chose in response of that question (immediate, delayed, or probabilistic amount). Formula for h-value:value = A / (1 + hO) p is probability of reward and O is odds against.The value of h indicates how the value of a reward and the probability of its occurrence decreases. The data are computerized and reflect delay discounting and impulsivity (higher discounting and higher Probability discounting shows greater impulsivity). A total score is not computed for this task.

Time frame:
Baseline and Week 16
Reported as:
Mean · unitless
Mean Change From Baseline to Week 16 in Delay and Probability Discounting Task (DPDT) - Experiential Discounting Task Scores
unitlessBrexpiprazole
Delay Discounting Task k value-103.167142 ± 414.497480
Probability Discounting Task h value2.866008 ± 168.230663
Statistical analysis
  • Brexpiprazole · t-test, 2 sided · p = 0.2923
  • Brexpiprazole · t-test, 2 sided · p = 0.9416
SecondaryChange From Baseline to Week 16 in the Mean Number of Impulsive Choices in the Delayed Reward Task (DRT)

Delay discounting was a participant-completed task considered as an index of impulsive behavior. It measured the extent to which the value of a reward decreased as the delay to obtaining that reward increased. During a training session, a single button with letter A or B appeared on the screen. The participant had to wait until the letter began to flash, and press the button only once. An amount of money was added to a counter and another single button appeared. During the test session, both buttons with letters A and B appeared on the screen. The participant had to choose one of the letters that remained; the other disappeared. The participant had to wait until the letter began to flash and then press the button again. An amount of money was added to the counter, and both letters appeared again. The data are computerized and reflect delay discounting and impulsivity (higher discounting shows greater impulsivity). A total score was not calculated for this task.

Time frame:
Baseline and Week 16
Reported as:
Mean · Number of Impulsive Choices
Change From Baseline to Week 16 in the Mean Number of Impulsive Choices in the Delayed Reward Task (DRT)
Number of Impulsive ChoicesBrexpiprazole
Change From Baseline to Week 16 in the Mean Number of Impulsive Choices in the Delayed Reward Task (DRT)8.9 ± 26.4
Statistical analysis
  • Brexpiprazole · t-test, 2 sided · p = 0.1815
SecondaryMean Change From Baseline to Week 16 in Food Delay Discounting Task

Delay discounting was a participant-completed task considered as an index of impulsive behavior. The participant chooses between a reward they could have today and another that they could get after a specified amount of time. The participant would not receive the rewards, but was asked to make decisions as though he or she were really going to receive them. AUC is defined as area under the concentration-time curve; AUC for food is presented below. The data are computerized and reflect delay discounting and impulsivity (higher discounting shows greater impulsivity). To calculate the AUC, the "X-axis" is "days", "Y-axis" is "Food value", the actual area underneath the curve was calculated by summing the results for each delay and present value pair: x2 -x1\[(y1 + y2)/2\], where x1 and x2 are successive delays and y1 and y2 are the present values associated with those delays. The AUC can range from 1 (no discounting) to 0 (maximum discounting).

Time frame:
Baseline and Week 16
Reported as:
Mean · unitless
Mean Change From Baseline to Week 16 in Food Delay Discounting Task
unitlessBrexpiprazole
Mean Change From Baseline to Week 16 in Food Delay Discounting Task0.037 ± 0.356
Statistical analysis
  • Brexpiprazole · t-test, 2 sided · p = 0.6648
  • Brexpiprazole · t-test, 2 sided · p = 0.9812
SecondaryMean Change From Baseline to Week 16 in Money Delay Discounting Task

Delay discounting was a participant-completed task considered as an index of impulsive behavior. The participant chose between a reward they could have today and another that they could get after a specified amount of time. The participant would not receive the rewards, but was asked to make decisions as though he or she were really going to receive them. AUC is defined as area under the concentration-time curve; AUC for money is presented below. The data are computerized and reflect delay discounting and impulsivity (higher discounting shows greater impulsivity). To calculate the AUC, the "X-axis" is "days", "Y-axis" is "Money value", the actual area underneath the curve was calculated by summing the results for each delay and present value pair: x2 -x1\[(y1 + y2)/2\], where x1 and x2 are successive delays and y1 and y2 are the present values associated with those delays. The AUC can range from 1 (no discounting) to 0 (maximum discounting).

Time frame:
Baseline and Week 16
Reported as:
Mean · unitless
Mean Change From Baseline to Week 16 in Money Delay Discounting Task
unitlessBrexpiprazole
Mean Change From Baseline to Week 16 in Money Delay Discounting Task0.001 ± 0.285
SecondaryMean Change From Baseline to Week 16 in Barratt Impulsiveness Scale (BIS) 11-Item

The BIS-11 was a participant-rated scale designed to assess impulsive personality traits. The BIS-11 consisted of 30 items scored on a 4-point scale ranging from 1 (rarely/never) to 4 (almost always/always). The scores provided information to assess 6 first-order factors (attention, motor, self-control, cognitive complexity, perseverance, and cognitive instability impulsiveness) and 3 second-order factors (motor impulsiveness, non-planning impulsiveness, and attentional impulsiveness). The total score ranged from 30 to 120, with higher scores indicating impulsive personality traits. It took 10 to 15 minutes to complete the BIS-11. The BIS-11 was administered at the following visits: Baseline and Week 16/ET.

Time frame:
Baseline and Week 16
Reported as:
Mean · Units on a scale
Mean Change From Baseline to Week 16 in Barratt Impulsiveness Scale (BIS) 11-Item
Units on a scaleBrexpiprazole
Mean Change From Baseline to Week 16 in Barratt Impulsiveness Scale (BIS) 11-Item-4.8 ± 11.3
Statistical analysis
  • Brexpiprazole · t-test, 2 sided · p = 0.0306

Adverse events

Collected over Adverse events were reported from the signing of the informed consent until the 30-day (+2) follow-up visit.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Brexpiprazole—0/49 (0%)14/49 (28.6%)
Most frequent other events
Most frequent other events
EventBrexpiprazole
InsomniaPsychiatric disorders7/49
SomnolenceNervous system disorders4/49
NauseaGastrointestinal disorders3/49
Weight increasedInvestigations3/49
SedationNervous system disorders3/49

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Brexpiprazole
Mean26.1 ± 5.0
Sex: Female, Male
Sex: Female, Male(Participants)Brexpiprazole
Female18
Male31
08

Study locations

22 sites
  • Cerritos, California 90703, United States
  • Chula Vista, California 92105, United States
  • Costa Mesa, California 92626, United States
  • Long Beach, California 90806, United States
  • Oakland, California 94612, United States
  • Oceanside, California 92056, United States
  • Pico Rivera, California 90660, United States
  • Riverside, California 92506, United States
  • San Diego, California 92102, United States
  • San Diego, California 92123, United States
  • Santa Ana, California 92705, United States
  • Torrance, California 90502, United States
  • Fort lauderdale, Florida 33334, United States
  • Atlanta, Georgia 30308, United States
  • Hoffman Estates, Illinois 60169, United States
  • Lake Charles, Louisiana 70629, United States
  • Rochester, New York 14618, United States
  • Philadelphia, Pennsylvania 19139, United States
  • Memphis, Tennessee 38119, United States
  • Dallas, Texas 75231, United States
  • Dallas, Texas 75243, United States
  • Houston, Texas 77007, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2013, a primary completion of Sep 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2016, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2013
First posted
Dec 17, 2013
Start
Nov 2013
Primary completionActual
Sep 2014
CompletionActual
Oct 2014
Results first posted
Mar 29, 2016
Last update
Mar 29, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02013622
Responsible party
Sponsor
First posted
Dec 17, 2013
Start date
Nov 2013
Primary completion
Sep 2014
Completion
Oct 2014
Results posted
Mar 29, 2016
Last update
Mar 29, 2016

Study contacts

Junichi Hashimoto, PhD
study director · Otsuka Pharmaceutical Co., Ltd Japan (OPCJ)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexpiprazole

Start the discussion